TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23072285

Group type: EXPERIMENTAL
Intervention: Bovine-derived hydroxyapatite (BHA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: β-tricalcium phosphate (β-TCP)
Number of subjects: 23
Study: 20138778

Group type: EXPERIMENTAL
Intervention: Daily respiratory physiotherapy interventions until discharge
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard medical/nursing care involving a clinical pathway
Number of subjects: 76
Study: 18367284

Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Wheat bran bread
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rye bread
Number of subjects: 121

Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 121
Study: 15123946

Group type: EXPERIMENTAL
Intervention: Intraarticular injection for pain relief
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 19
Study: 11159262

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study: 11398300

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study: 7511501

Group type: EXPERIMENTAL
Intervention: Bispectral index analysis of EEG during induction of anesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Power spectral analysis of EEG
Number of subjects: 39
Study: 3278497

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg i.v.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal saline (placebo) i.v.
Number of subjects: 7
Study: 29466249

Group type: EXPERIMENTAL
Intervention: TPP-related compounds (specifically bis-TPP, 2-butene-1,4-bis-TPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPP-related compounds (general)
Number of subjects: 0
Study: 28803715

Group type: EXPERIMENTAL
Intervention: 20μg Hepatitis E Virus (HEV) p179 vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 30μg HEV vaccine p239 Hecolin (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 40μg Hepatitis E Virus (HEV) p179 vaccine
Number of subjects: 120
Study: 25680558

Group type: EXPERIMENTAL
Intervention: Continuation of trabectedin treatment after six cycles (27 patients)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Interruption of trabectedin treatment after six cycles (26 patients)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Continuation of trabectedin treatment (27 patients)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Interruption of trabectedin treatment (26 patients)
Number of subjects: 178
Study: 23053269

Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg (single oral dose)
Number of subjects: 27
Study: 22157480

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 38
Study: 18841294

Group type: EXPERIMENTAL
Intervention: Bivalirudin bolus
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous infusion of Bivalirudin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: UFH + eptifibatide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enoxaparin + eptifibatide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bivalirudin + eptifibatide
Number of subjects: 10
Study: 16817264

Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 20 minutes
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 40 minutes
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Acupuncture with needle-retaining time of 60 minutes
Number of subjects: 251
Study: 12500072

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Blinded rater's guess of treatment assignment
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 128
Study: 10623703

Group type: EXPERIMENTAL
Intervention: Docetaxel at a dose of 100 mg/m(2) intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 80
Study: 9181181

Group type: EXPERIMENTAL
Intervention: 65 mg NET-90
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mg NET-90
Number of subjects: 100
Study: 8251354

Group type: EXPERIMENTAL
Intervention: Combination of cetirizine (10 mg at night) and ranitidine (150 mg twice daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of terfenadine (120 mg twice daily) and ranitidine (150 mg twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cetirizine (10 mg at night)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Terfenadine (120 mg twice daily)
Number of subjects: 28
Study: 2994577

Group type: EXPERIMENTAL
Intervention: CPA.ACNU.VCR (CNV, n = 64)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ADR.ACNU.VCR (ANV, n = 52)
Number of subjects: 116
Study: 29956072

Group type: EXPERIMENTAL
Intervention: Peer parent support intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent Patient Activation Measure‐Mental Health (P‐PAM‐MH)
Number of subjects: 0
Study: 29985447

Group type: EXPERIMENTAL
Intervention: Adapted Taekwondo (TKD) training
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study: 27018037

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 25099550

Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 14
Study: 22137189

Group type: EXPERIMENTAL
Intervention: Peer role play (RP)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Standardized patients (SP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study: 19882199

Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt videolaryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional GlideScope videolaryngoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 100
Study: 17638930

Group type: EXPERIMENTAL
Intervention: BMI 25 to 29.9
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: BMI 22.5 to 24.9
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: BMI < 22.5
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: BMI >= 35
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Lower BMI without edema
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Baseline BMI
Number of subjects: 7599
Study: 12769445

Group type: EXPERIMENTAL
Intervention: Oat bran intervention (60 g oat bran daily, corresponding to 20 g dietary fiber)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 11106305

Group type: EXPERIMENTAL
Intervention: + TP (Tryptophan included)
Number of subjects: 13

Group type: COMPARATOR
Intervention: - TP (Tryptophan not included)
Number of subjects: 13
Study: 9075465

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8465164

Group type: EXPERIMENTAL
Intervention: Ground reaction force feedback through auditory output (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ground reaction force feedback (control group)
Number of subjects: 40
Study: 3928015

Group type: EXPERIMENTAL
Intervention: 0.15 mg vitamin K1 per week
Number of subjects: 47

Group type: COMPARATOR
Intervention: 20.15 mg vitamin K1 per week
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 10 mg vitamin K1 per day
Number of subjects: 47
Study: 30679522

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (simulated night shift work)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Circadian alignment (simulated day shift work)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study: 28829005

Group type: EXPERIMENTAL
Intervention: Veder Contact Method (VCM)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Care-As-Usual (Control)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Qualitative feedback from caregivers and managers on VCM
Number of subjects: 111
Study: 25925994

Group type: EXPERIMENTAL
Intervention: Crenotherapy with sodium chloride sulfate hyperthermal water rich in mineral salts
Number of subjects: 60

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 60
Study: 23856575

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 20

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 20
Study: 21616952

Group type: EXPERIMENTAL
Intervention: Home-based management (n = 143)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Clinic-based management (n = 137)
Number of subjects: 280
Study: 19185249

Group type: EXPERIMENTAL
Intervention: Trypan blue staining in nondiabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trypan blue staining in diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsules of nondiabetic patients without trypan blue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsules of diabetic patients without trypan blue
Number of subjects: 0
Study: 18200368

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercises)
Number of subjects: 20
Study: 15185837

Group type: EXPERIMENTAL
Intervention: Guided self-help treatment (GSH)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Minimal guided self-help treatment (M-GSH)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 161
Study: 10892758

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Non-invasive strategy
Number of subjects: 2457
Study: 9366281

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 1551787

Group type: EXPERIMENTAL
Intervention: Fluoxetine (8 weeks treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (8 weeks treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluoxetine and Placebo
Number of subjects: 32
Study: 3925744

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN), 40 to 120 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nifedipine, 40 to 120 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intracoronary nitroglycerin, 200 micrograms
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination therapy of ISDN and calcium antagonist
Number of subjects: 19
Study: 30797397

Group type: EXPERIMENTAL
Intervention: D-PTSD class (dissociative subtype of PTSD)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Other classes (non-dissociative subtypes)
Number of subjects: 258
Study: 29037516

Group type: EXPERIMENTAL
Intervention: Statin users (71 patients, 21.1%)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 336
Study: 27829576

Group type: COMPARATOR
Intervention: eHealth
Number of subjects: 373
Study: 24754314

Group type: EXPERIMENTAL
Intervention: Long-acting injectable paliperidone palmitate (PP)
Number of subjects: 0
Study: 23254945

Group type: EXPERIMENTAL
Intervention: Endoscopic stapler device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Number of subjects: 100
Study: 20582970

Group type: EXPERIMENTAL
Intervention: LSA2L2-type maintenance therapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: 6-mercaptopurine (6-MP)/methotrexate (MTX) with vincristine (VCR) and dexamethasone (DEX) pulse
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Standard-risk (SR) patients
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: High-risk (HR) patients
Number of subjects: 201
Study: 18839777

Group type: EXPERIMENTAL
Intervention: Cockcroft-Gault (CG) formula
Number of subjects: 3316

Group type: EXPERIMENTAL
Intervention: Modification of Diet in Renal Disease (MDRD) formula
Number of subjects: 3316

Group type: COMPARATOR
Intervention: Serum creatinine alone
Number of subjects: 3316
Study: 16637755

Group type: EXPERIMENTAL
Intervention: General stress exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frustration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Startle eyeblink reactions during stress
Number of subjects: 0
Study: 14585938

Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg twice daily
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1851
Study: 10992752

Group type: EXPERIMENTAL
Intervention: Patient education for osteoarthritis of the knee
Number of subjects: 0
Study: 8773910

Group type: EXPERIMENTAL
Intervention: Post‐hepatitis C liver cirrhosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcoholic liver cirrhosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-cirrhotic specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Idiopathic portal hypertension specimens
Number of subjects: 0
Study: 1312854

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (20-40 mg twice daily)
Number of subjects: 0
Study: 31493297

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stabilisation Splint (SS)
Number of subjects: 96
Study: 31102396

Group type: COMPARATOR
Intervention: Fiber posts (Rely X, 3M‐ESPE) with composite core build‐up (Filtek Bulk Fill Posterior, 3M‐ESPE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One‐piece milled post and core from fiber reinforced composite blocks (Trilor, Bioloren)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One‐piece milled post and core from hybrid ceramic disks (Ambarino, Creamed)
Number of subjects: 30
Study: 27875013

Group type: EXPERIMENTAL
Intervention: Intensive care unit survivorship concept
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Longitudinal qualitative interviews
Number of subjects: 17
Study: 26512563

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (PRD group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline (PRS group)
Number of subjects: 67
Study: 24494280

Group type: EXPERIMENTAL
Intervention: Acupuncture rehabilitation group (acupuncture at specific points plus comprehensive rehabilitation therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simple rehabilitation group (comprehensive rehabilitation therapy only)
Number of subjects: 120
Study: 20635176

Group type: EXPERIMENTAL
Intervention: Harassment condition
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High hostility group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonharassment condition
Number of subjects: 99

Group type: COMPARATOR
Intervention: Low hostility group
Number of subjects: 99
Study: 21563716

Group type: EXPERIMENTAL
Intervention: Nurse case management and home environmental interventions
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group interventions (visual assessment, education, bed/pillow dust mite encasings, treatment of lead‐based paint hazards)
Number of subjects: 121
Study: 17388767

Group type: EXPERIMENTAL
Intervention: Acupuncture group (n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham control group (n = 27)
Number of subjects: 56
Study: 16269592

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12040140

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E epsilon4 allele
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Control group (no epsilon4 allele)
Number of subjects: 1998
Study: 10217340

Group type: EXPERIMENTAL
Intervention: Fluconal (Libbs Farmacêutica Ltda, São Paulo, Brazil)
Number of subjects: 24
Study: 8521433

Group type: EXPERIMENTAL
Intervention: 1-min active mouthrinse with toothpaste-foam combined with 10 ml of water after brushing for 2 min
Number of subjects: 7

Group type: COMPARATOR
Intervention: 3 thorough rinsings of approximately 15 ml water each after brushing for 2 min
Number of subjects: 7
Study: 2089286

Group type: EXPERIMENTAL
Intervention: Continuous therapy with 400 mg/day of cimetidine for 1 year
Number of subjects: 90

Group type: COMPARATOR
Intervention: Seasonal therapy with 400 mg/day of cimetidine for 4 months a year
Number of subjects: 90
Study: 511673

Group type: EXPERIMENTAL
Intervention: Passive recovery (PR)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active recovery below anaerobic threshold (AR less than AT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active recovery above anaerobic threshold (AR greater than AT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Active recovery above anaerobic threshold while breathing 100% oxygen (AR greater than AT + O2)
Number of subjects: 9
Study: 30216697

Group type: EXPERIMENTAL
Intervention: Commercial infant products
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Fortified staples (maize meal and wheat flour)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Fortified staples consumers vs nonconsumers
Number of subjects: 715

Group type: COMPARATOR
Intervention: Complementary diet nutrient densities
Number of subjects: 715

Group type: COMPARATOR
Intervention: Calcium intakes
Number of subjects: 715
Study: 27852613

Group type: EXPERIMENTAL
Intervention: 5 g vitamin C-enriched gelatin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 g vitamin C-enriched gelatin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study: 25060839

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (8 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (16 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (8/2, 8/8, 8/16, 16/4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Naloxone (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heroin (100 mg)
Number of subjects: 12
Study: 23623647

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily
Number of subjects: 4628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study: 21720299

Group type: EXPERIMENTAL
Intervention: sinuforte (one dose administered daily into each half of the nasal cavity)
Number of subjects: 30
Study: 19854960

Group type: EXPERIMENTAL
Intervention: Sonographically guided injections of hyaluronic acid (HA)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Blind injections of hyaluronic acid (HA)
Number of subjects: 89
Study: 16412748

Group type: EXPERIMENTAL
Intervention: 2.5 mg of letrozole
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg of letrozole
Number of subjects: 72
Study: 15260909

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg b.i.d.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Dothiepin 25 mg mane followed by 50 mg nocte
Number of subjects: 88
Study: 11418255

Group type: EXPERIMENTAL
Intervention: PPIP office‐based system implementation
Number of subjects: 748
Study: 9089821

Group type: EXPERIMENTAL
Intervention: Lithium prophylaxis
Number of subjects: 181

Group type: COMPARATOR
Intervention: No lithium prophylaxis
Number of subjects: 181
Study: 8095383

Group type: EXPERIMENTAL
Intervention: Atracurium (0.4 mg.kg‐1 BW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vecuronium (0.08 mg.kg‐1 BW)
Number of subjects: 40
Study: 3549842

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 19
Study: 29503044

Group type: EXPERIMENTAL
Intervention: SOS‐HAE group (intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual-practice group (control)
Number of subjects: 200
Study: 27475844

Group type: EXPERIMENTAL
Intervention: Thrombectomy and intracoronary administration of tirofiban (Group A)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Thrombectomy (Group B)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 240
Study: 24930201

Group type: EXPERIMENTAL
Intervention: Standard treatment plus a 12-week post-exacerbation pulmonary rehabilitation (PEPR) programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment without pulmonary rehabilitation (CTWPR)
Number of subjects: 60
Study: 23678498

Group type: EXPERIMENTAL
Intervention: Home visiting intervention consisting of 44 visits from the third trimester of pregnancy to the child's second birthday.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Home visiting intervention with trained clinical psychologists conducting visits.
Number of subjects: 440
Study: 20127562

Group type: EXPERIMENTAL
Intervention: Low-dose lomitapide (AEGR-733)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose MTP inhibitors (not specified)
Number of subjects: 0
Study: 18318082

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study: 15942467

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 15765619

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 10510989

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (gum)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nasal spray
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Inhaler
Number of subjects: 504
Study: 7742714

Group type: EXPERIMENTAL
Intervention: 100% hyperbaric oxygen (HBO) for 2 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: 100% normobaric oxygen (NBO) for 2 hours
Number of subjects: 26
Study: 2037209

Group type: EXPERIMENTAL
Intervention: Training program (three-hour duration, including small group discussion and role-playing exercises)
Number of subjects: 198